Skip to main content
Premium Trial:

Request an Annual Quote

Axys Creates Subsidiary To Market Combi Chem

Premium

SOUTH SAN FRANCISCO--Axys Pharmaceuticals, announced this month that is has formed a new wholly owned subsidiary called Axys Advanced Technologies. The new company, formerly the advanced technologies division of Axys, has been created to market Axys's combinatorial chemistry techniques. Axys Advanced Technologies produces and sells diversity libraries for general screening and directed libraries focused on specific protein targets. It also offers technology and follow-on medicinal chemistry services. Current customers for the new unit include Parke-Davis, Rhone-Poulenc Rorer, Pharmacia & Upjohn, Signal Pharmaceuticals, Protein Design Labs, and Daiichi Pharmaceutical of Japan.

Filed under

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.